Nurix Therapeutics, Inc.

NasdaqGM:NRIX Voorraadrapport

Marktkapitalisatie: US$1.8b

Nurix Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Nurix Therapeutics is Arthur Sands, benoemd in Sep2014, heeft een ambtstermijn van 11.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.37M, bestaande uit 10.6% salaris en 89.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde $ 5.41M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 4.1 jaar.

Belangrijke informatie

Arthur Sands

Algemeen directeur

US$6.4m

Totale compensatie

Percentage CEO-salaris10.58%
Dienstverband CEO11.7yrs
Eigendom CEO0.3%
Management gemiddelde ambtstermijn5.8yrs
Gemiddelde ambtstermijn bestuur4.1yrs

Recente managementupdates

Analyseartikel • May 12

Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being

Key Insights Nurix Therapeutics' Annual General Meeting to take place on 19th of May CEO Arthur Sands' total...

Recent updates

Seeking Alpha • Apr 09

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

Summary Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies. While cash reserves stand at $540.7M, NRIX faces a 12-month runway and will require additional funding to sustain its R&D-intensive pipeline. Read the full article on Seeking Alpha
Analyseartikel • Nov 16

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders have had their patience rewarded with a 30% share price jump in...
Analyseartikel • Oct 12

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) missed earnings with its latest quarterly results, disappointing...
Analyseartikel • Sep 30

Subdued Growth No Barrier To Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price

With a median price-to-sales (or "P/S") ratio of close to 10x in the Biotechs industry in the United States, you could...
Analyseartikel • Aug 18

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

NasdaqGM:NRIX 1 Year Share Price vs Fair Value Explore Nurix Therapeutics's Fair Values from the Community and select...
Analyseartikel • Jul 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • May 12

Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being

Key Insights Nurix Therapeutics' Annual General Meeting to take place on 19th of May CEO Arthur Sands' total...
Seeking Alpha • Apr 17

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Summary FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $135 million from its Gilead collaboration and could earn up to a total of $420 million in milestone payments for developing up to five protein degraders. Nurix's wholly owned BTK degrader Bexobrutideg is in phase 1b trials for relapsed/refractory B-cell malignancies, with plans to target inflammatory and autoimmune disorders as well. Besides the partnership with Gilead Sciences, the company is advancing its STAT6 protein degrader with Sanofi and antibody drug conjugate degraders as a new class of drugs to target disorders with Pfizer. Read the full article on Seeking Alpha
Analyseartikel • Apr 17

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • Mar 22

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has dived 25% in the last...
Seeking Alpha • Feb 18

Nurix Therapeutics: A Story To Monitor

Summary Nurix Therapeutics, Inc.'s shares have dropped some 40% due to limited 2025 data catalysts, despite promising Phase 1 results for NX-5948 in CLL, targeting pivotal trials in 2025. Nurix's DELigase platform leverages E3 ligases for protein modulation, aiming to degrade or elevate proteins, offering advantages over CRISPR and RNA interference methods. NX-5948 shows strong efficacy in heavily pre-treated CLL patients, with Fast Track and PRIME designations, but faces competition from BeiGene's similar BTK degrader. An initial analysis around NRIX stock follows in the paragraphs below. Read the full article on Seeking Alpha
Analyseartikel • Jan 30

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Nurix Therapeutics...
Seeking Alpha • Jan 05

Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me

Summary Nurix Therapeutics (NRIX) focuses on protein degradation in cancer treatment, with a current valuation of $1.4 billion and promising early-stage clinical data. NX-5948, a BTK degrader, shows high response rates in B-cell malignancies, with manageable safety profiles and FDA Fast Track designations. Financially, NRIX holds $99 million in cash and $349 million in marketable securities, but faces risks of future dilution and high execution expectations. Despite compelling early data, NRIX's high valuation and market hype suggest waiting for better entry points, making it a "Hold" for now, in my opinion. Read the full article on Seeking Alpha
Analyseartikel • Nov 07

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Despite an already strong run, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have been powering on, with a gain of...
Analyseartikel • Oct 31

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Nurix...
Seeking Alpha • Oct 08

Nurix: An Attractive Early-Stage Biotech Play

Summary Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain. Nurix's innovative approach and potential regulatory approvals make it a strong investment candidate for those seeking high-risk, high-reward opportunities. Read the full article on Seeking Alpha
Analyseartikel • Sep 07

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics, Inc.'s ( NASDAQ:NRIX ) price-to-sales (or "P/S") ratio of 24.1x might make it look like a strong...
Seeking Alpha • Sep 04

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Summary Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key programs include BTK, IKZF, and CBL-B targets, with notable molecules NX-5948, NX-2127, and NX-1607 showing potential in heavily pretreated B-cell malignancies. Strategic partnerships with Gilead, Sanofi, and Pfizer provide substantial financial backing, with up to $8.1 billion in potential milestone payments. Despite high valuation and limited near-term data catalysts, Nurix's innovative approach and big pharma interest warrant continued observation for future investment opportunities. Read the full article on Seeking Alpha
Analyseartikel • Jul 15

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, Nurix Therapeutics...
Seeking Alpha • Jun 19

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Summary Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional small molecules. Nurix's lead proprietary candidate NX-5948 showed promising results in a Phase 1a clinical study for CLL patients in data released this week, triggering a surge in the company's share price. Management hopes to guide its lead candidate into a pivotal study next year, opening up a potentially compelling market opportunity. More data - in NHL and immuno-oncology - will arrive this year, and Nurix continues to collaborate with three major Pharma companies - Gilead, Sanofi, and Pfizer. The bull run can therefore be sustained. Read the full article on Seeking Alpha
Analyseartikel • May 29

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

The Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has done very well over the last month, posting an excellent...
Seeking Alpha • Apr 15

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Summary Nurix Therapeutics raises $175 million in an upsized offering after a 168% stock return in the past six months. The biotech company is developing protein degraders, with NX-2127 and NX-5948, targeting B-cell malignancies. Nurix's protein degraders are focused on BTK, a target also addressed by Johnson & Johnson's popular drug Imbruvica. Hold rating advised: High-risk, high-reward due to innovative approach and competitive market; efficacy and safety data needed. Read the full article on Seeking Alpha
Analyseartikel • Apr 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have continued their recent momentum with a 28% gain in the last month...
Analyseartikel • Feb 20

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 6.3x Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be sending very bullish...
Seeking Alpha • Jan 16

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Summary Nurix Therapeutics remains a highly interesting science project, but the rubber has yet to hit the road on their clinical projects. The company's BTK degraders are showing early signs of life, but the competition in the market and expenses are concerns. Nurix has enough assets to fund operations for another 6 to 7 quarters, but a cash infusion may be needed later this year. Read the full article on Seeking Alpha
Analyseartikel • Dec 29

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyseartikel • Oct 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

To the annoyance of some shareholders, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares are down a considerable 29% in...
Analyseartikel • Oct 13

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Shareholders in Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be thrilled to learn that the analysts have just delivered...
Analyseartikel • Sep 30

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Apr 18

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • Apr 15

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyseartikel • Nov 28

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyse CEO-vergoeding

Hoe is Arthur Sands's beloning veranderd ten opzichte van Nurix Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Feb 28 2026n/an/a

-US$295m

Nov 30 2025US$6mUS$675k

-US$264m

Aug 31 2025n/an/a

-US$245m

May 31 2025n/an/a

-US$207m

Feb 28 2025n/an/a

-US$208m

Nov 30 2024US$6mUS$613k

-US$194m

Aug 31 2024n/an/a

-US$177m

May 31 2024n/an/a

-US$165m

Feb 29 2024n/an/a

-US$145m

Nov 30 2023US$4mUS$591k

-US$144m

Aug 31 2023n/an/a

-US$149m

May 31 2023n/an/a

-US$157m

Feb 28 2023n/an/a

-US$179m

Nov 30 2022US$9mUS$572k

-US$180m

Aug 31 2022n/an/a

-US$171m

May 31 2022n/an/a

-US$154m

Feb 28 2022n/an/a

-US$135m

Nov 30 2021US$5mUS$539k

-US$117m

Aug 31 2021n/an/a

-US$99m

May 31 2021n/an/a

-US$89m

Feb 28 2021n/an/a

-US$63m

Nov 30 2020US$17mUS$521k

-US$43m

Aug 31 2020n/an/a

-US$37m

May 31 2020n/an/a

-US$21m

Feb 29 2020n/an/a

-US$24m

Nov 30 2019US$1mUS$474k

-US$22m

Compensatie versus markt: De totale vergoeding ($USD 6.37M ) Arthur } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.45M ).

Compensatie versus inkomsten: De vergoeding van Arthur is gestegen terwijl het bedrijf verliesgevend is.

CEO

Arthur Sands (63 yo)

11.7yrs
Tenure
US$6,374,138
Compensatie

Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Arthur Sands
CEO, President & Director11.7yrsUS$6.37m0.30%
$ 5.4m
Johannes Van Houte
Chief Financial Officer10.2yrsUS$2.30m0.036%
$ 658.9k
Gwenn Hansen
Chief Scientific Officer5.9yrsUS$2.50m0.12%
$ 2.1m
Christine Ring
Chief Legal Officer6.7yrsUS$2.26m0.018%
$ 320.8k
John Kuriyan
Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Arthur Weiss
Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Rita Kwong
Senior Accounting Managerno datageen gegevensgeen gegevens
Pasit Phiasivongsa
Chief Technical Officer2yrsgeen gegevensgeen gegevens
Jason Kantor
Chief Business Officer5.8yrsgeen gegevensgeen gegevens
Christopher Phelps
Senior VP & Head of Early Drug Discovery5.3yrsgeen gegevensgeen gegevens
Buckley Kohlhauff
Senior Vice President of Information Technology4.3yrsgeen gegevensgeen gegevens
Bev Benson
VP & Head of Clinical Science4.3yrsgeen gegevensgeen gegevens
5.8yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van NRIX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Arthur Sands
CEO, President & Director11.7yrsUS$6.37m0.30%
$ 5.4m
John Kuriyan
Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Arthur Weiss
Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Julia Gregory
Independent Chairman6.8yrsUS$258.97k0.010%
$ 188.5k
Ronald Levy
Member of Medical Advisory Board3.3yrsgeen gegevensgeen gegevens
Judith Reinsdorf
Independent Director4.6yrsUS$229.07k0%
$ 0
Roy Baynes
Independent Director1.2yrsUS$668.79k0%
$ 0
David Lacey
Independent Director10.1yrsUS$226.57k0.032%
$ 584.4k
Paul Silva
Independent Director4.6yrsUS$230.32k0%
$ 0
Edward Saltzman
Independent Director3.7yrsUS$220.22k0%
$ 0
Roger Dansey
Independent Directorless than a yearUS$421.68kgeen gegevens
Anil Kapur
Independent Director1.6yrsUS$217.93k0%
$ 0
4.1yrs
Gemiddelde duur
69yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NRIX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/22 07:43
Aandelenkoers aan het einde van de dag2026/05/22 00:00
Inkomsten2026/02/28
Jaarlijkse inkomsten2025/11/30

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Nurix Therapeutics, Inc. wordt gevolgd door 25 analisten. 17 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Brian SkorneyBaird
Joel BeattyBaird
Zhiqiang ShuBerenberg